SJ-733
CAS No. 1424799-20-1
SJ-733 ( +)-SJ733 | SJ000557733 | SJ-557733 )
产品货号. M11792 CAS No. 1424799-20-1
SJ-733 (SJ000557733;SJ-557733) 是一种靶向 ATP4 的抗疟化合物,ATP4 是一种阳离子转运 ATP 酶,负责维持寄生虫细胞内较低的 Na(+) 水平。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称SJ-733
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述SJ-733 (SJ000557733;SJ-557733) 是一种靶向 ATP4 的抗疟化合物,ATP4 是一种阳离子转运 ATP 酶,负责维持寄生虫细胞内较低的 Na(+) 水平。
-
产品描述SJ-733 (SJ000557733;SJ-557733) is an anti-malarial compound that targets ATP4, a cation-transporting ATPase responsible for maintaining low intracellular Na(+) levels in the parasite; displays high potency in vitro against all tested strains of P. falciparum with EC50 of 10-60 nM; kills parasites and the high fitness cost associated with resistance-conferring mutations appear to slow and suppress the selection of highly drug-resistant mutants in vivo; high oral bioavailabilityParasite Infection Phase 1 Clinical.
-
体外实验(+)-SJ733 binds to a single receptor site in P. falciparum-infected erythrocytes with equivalent affinity to its growth-inhibitory potency (kd=50 nM). (+)-SJ733 has not exhibited either significant safety liabilities at any dose in extensive profiling in vitro or significant safety or tolerability liabilities in either single- or repeat-dose studies at any dose tested in any preclinical species (no observed adverse effect level and maximum tolerated dose >240 mg/kg from 7-d repeat dosing study in rat). Therefore, (+)-SJ733 is expected to have a safety margin of at least 43-fold.
-
体内实验Treatment of P. falciparum-infected NOD-scid IL2Rγnull mice with (+)-SJ733 causes rapid clearance of parasites, which are 80% depleted within the first 24 h and undetectable by 48 h. (+)-SJ733 is highly potent and efficacious against P. falciparum 3D70087/N9 in vivo when administered as four sequential daily oral doses in the NOD-scid IL2Rγnull mouse model, with a 90% effective dose, (ED90 1.9 mg/kg) and exposure [area under the curve at ED90 (AUCED90), 1.5 μM?h] superior to artesunate (11.1 mg/kg; AUCED90 not determined), chloroquine (4.3 mg/kg; AUCED90 3.1 μM?h), and pyrimethamine (0.9 mg/kg; AUCED90 5. μM?h) in the same model. When treated with the ED90 dose, (+)-SJ733 concentrations in blood remain above the average in vitro EC90 for 6 to 10 h after each dose.
-
同义词+)-SJ733 | SJ000557733 | SJ-557733
-
通路Microbiology/Virology
-
靶点Parasite
-
受体Parasite
-
研究领域Infection
-
适应症Parasite Infection
化学信息
-
CAS Number1424799-20-1
-
分子量468.412
-
分子式C24H16F4N4O2
-
纯度>98% (HPLC)
-
溶解度DMSO : 50 mg/mL 106.75 mM
-
SMILESO=C([C@@H](C1=C2C=CC=C1)[C@@H](C3=CC=CN=C3)N(CC(F)(F)F)C2=O)NC4=CC=C(F)C(C#N)=C4
-
化学全称(3S,4S)-N-(3-Cyano-4-fluorophenyl)-1-oxo-3-(3-pyridinyl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydro-4-isoquinolinecarboxamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Jiménez-Díaz MB, et al. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5455-62.
2. Crawford ED, et al. PLoS One. 2017 May 22;12(5):e0178163.
3. Mogollon CM, et al. PLoS One. 2016 Dec 20;11(12):e0168362.
产品手册
关联产品
-
Ganaplacide
Ganaplacide (KAF156, GNF-156) 是一种新型抗疟临床候选化合物,对恶性疟原虫化合物敏感和耐药菌株具有杀血液裂殖活性,IC50 为 6-17.4 nM。
-
Pafuramidine
Pafuramidine (DB289) 是一种具有口服活性的 Furamidine (HY-110137A) 前体。Pafuramidine 是一种有效的抗寄生虫剂,可用于锥虫病、肺囊虫肺炎和疟疾的研究。
-
Quinidine
奎尼丁是抗疟药奎宁的立体异构体,也是 Ia 类抗心律失常药。用于治疗心律失常和疟疾。
021-51111890
购物车()
sales@molnova.cn

